MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers, including oncologists, pharmacists and nurses. Podcasts are brought to you by MediCom Worldwide, Inc., an accredited, independent medical education company. Podcasts are intended for licensed adul ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Third-generation FLT3 inhibitors in clinical development
2:42
2:42
Afspil senere
Afspil senere
Lister
Like
Liked
2:42
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CAR T case study in acute myeloid leukemia
5:49
5:49
Afspil senere
Afspil senere
Lister
Like
Liked
5:49
Dr. Sallman describes a patient case demonstrating promise in the further study and potential use of CAR T-cell therapy for patients with AML.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi
2:23
2:23
Afspil senere
Afspil senere
Lister
Like
Liked
2:23
Dr. Perl gives guidance on providing optimal patient therapy when prescribing midostaurin with a strong CYP3A4 inhibitor.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance
3:58
3:58
Afspil senere
Afspil senere
Lister
Like
Liked
3:58
In this audio activity, Dr. Goldberg describes his approach to patients with idiopathic or clonal cytopenias of undetermined significance (ICUS and CCUS).Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
When to consider iron chelation therapy for a transplant-eligible patient
3:56
3:56
Afspil senere
Afspil senere
Lister
Like
Liked
3:56
Listen as Dr. Goldberg explains his approach to iron chelation therapy in patients who are, or may be within the next 5-10 years, eligible for transplant.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
53-year-old woman presenting with severe fatigue and bruising
3:58
3:58
Afspil senere
Afspil senere
Lister
Like
Liked
3:58
Hematopathologist Dr. Khoury presents a case snapshot showing the complexities of diagnosing AML, describing the importance of morphology, flow cytometry, cytogenetics, and molecular diagnostics.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy
4:00
4:00
Afspil senere
Afspil senere
Lister
Like
Liked
4:00
Dr. O'Reilly discusses the new subcategories of pancreatic cancer that have emerged, and which are laying the groundwork for a biomarker-driven approach to therapy.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?
2:40
2:40
Afspil senere
Afspil senere
Lister
Like
Liked
2:40
Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Predictors of response to lenalidomide in a non-del(5q) MDS patient
3:03
3:03
Afspil senere
Afspil senere
Lister
Like
Liked
3:03
Listen as Dr. Goldberg discusses, in just under two minutes, the predictors of response to lenalidomide in a non-del(5q) MDS patient.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What are the pros and cons of radiation therapy?
2:29
2:29
Afspil senere
Afspil senere
Lister
Like
Liked
2:29
Listen as Dr. Matasar discusses the pros and cons of radiation therapy, and who should be offered this therapy.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma?
3:01
3:01
Afspil senere
Afspil senere
Lister
Like
Liked
3:01
Listen as Dr. Matasar discusses survivorship care for patients who have been treated for classical Hodgkin lymphoma, including late effects of treatment.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Second primary malignancies associated with lenalidomide maintenance
2:53
2:53
Afspil senere
Afspil senere
Lister
Like
Liked
2:53
Dr. Jacob Laubach discusses second primary malignancies associated with lenalidomide maintenance in the transplant and post-transplant setting.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Impact of consolidation therapy in patients post-transplant
3:09
3:09
Afspil senere
Afspil senere
Lister
Like
Liked
3:09
Dr. Laubach discusses the impact of consolidation therapy in patients post-transplant, referencing results of the CTN StaMINA trial.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Bortezomib as an alternate strategy for maintenance therapy.
2:32
2:32
Afspil senere
Afspil senere
Lister
Like
Liked
2:32
Dr. Jacob Laubach discusses bortezomib as an alternate strategy to lenalidomide for maintenance therapy in patients with multiple myeloma.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What may be the future role for brentuximab vedotin in newly diagnosed Hodgkin lymphoma?
2:35
2:35
Afspil senere
Afspil senere
Lister
Like
Liked
2:35
Listen as Dr. Matasar discusses the future role of brentuximab vedotin in patients with newly diagnosed classical Hodgkin lymphoma.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Has MRD testing become a standard of care in multiple myeloma?
3:22
3:22
Afspil senere
Afspil senere
Lister
Like
Liked
3:22
Dr. Ruben Niesvizky discusses MRD testing and how it has become a standard of care in multiple myeloma, as well as future directions in MRD testing that will improve outcomes in these patients.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Precision Promise [SM] Initiative: What is it designed to achieve?
4:32
4:32
Afspil senere
Afspil senere
Lister
Like
Liked
4:32
Dr. O'Reilly provides an insightful overview of how the emerging use of precision medicine and the Precision Promise [SM] initiative will impact the new drug approval process in pancreatic cancer.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study
8:26
8:26
Afspil senere
Afspil senere
Lister
Like
Liked
8:26
Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What are the optimal imaging methods to determine extent of bone disease in newly diagnosed MM?
3:18
3:18
Afspil senere
Afspil senere
Lister
Like
Liked
3:18
Dr. Ruben Niesvizky discusses newer approaches for imaging in patients who have multiple myeloma with bone disease, including the benefits of combining modalities such MRI and PET scan.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The standard of care for patients receiving lenalidomide or thalidomide who are at high risk for VTE
3:36
3:36
Afspil senere
Afspil senere
Lister
Like
Liked
3:36
Dr. Ruben Niesvizky discusses clinical approaches to managing the risk of developing VTE in myeloma patients receiving immunomodulating agents such as lenalidomide or thalidomide.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How do I dose daratumumab, lenalidomide and dexamethasone in the combination regimen?
1:59
1:59
Afspil senere
Afspil senere
Lister
Like
Liked
1:59
In under two minutes, Dr. Carol Ann Huff will discuss how to dose daratumumab in conjunction with lenalidomide and dexamethasone in patients with multiple myeloma.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Is there a connection between pancreatic cancer and new-onset diabetes?
8:26
8:26
Afspil senere
Afspil senere
Lister
Like
Liked
8:26
Dr. Anil Rustgi discusses a clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
CPX versus 7 and 3 conventional chemotherapy in older adults with AML
3:16
3:16
Afspil senere
Afspil senere
Lister
Like
Liked
3:16
Dr. Stuart Goldberg briefly summarizes updates on CPX-351, a liposomal form of cytarabine and daunorubicin that allows for office infusion vs. standard consolidation requiring hospitalization.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How long should I be infusing carfilzomib intravenously?
2:55
2:55
Afspil senere
Afspil senere
Lister
Like
Liked
2:55
Listen as Dr. Huff discusses the infusion duration for carfilzomib in patients with multiple myeloma.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What is the current status of immunotherapy in pancreatic cancer?
4:37
4:37
Afspil senere
Afspil senere
Lister
Like
Liked
4:37
Listen as Dr. O'Reilly discusses the the current status of immunotherapy in pancreatic cancer.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Measuring Frailty in Patients Being Treated for Multiple Myeloma
1:49
1:49
Afspil senere
Afspil senere
Lister
Like
Liked
1:49
Listen for just under two minutes as Dr. Harvey explains measuring frailty in patients being treated for multiple myeloma.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant IDH2
4:04
4:04
Afspil senere
Afspil senere
Lister
Like
Liked
4:04
Dr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How do I dose daratumumab, bortezomib and dexamethasone in the combination regimen?
3:17
3:17
Afspil senere
Afspil senere
Lister
Like
Liked
3:17
Listen as Dr. Carol Ann Huff discusses how to dose daratumumab, bortezomib and dexamethasone in the combination regimen.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Update on the CALGB-100104 (Alliance) randomized trial
3:26
3:26
Afspil senere
Afspil senere
Lister
Like
Liked
3:26
Listen as Dr. Philip McCarthy provides an update on the CALGB-100104 (Alliance) randomized trial.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How does the safety profile of the new and emerging anti-PD 1 antibodies differ from chemotherapy?
1:55
1:55
Afspil senere
Afspil senere
Lister
Like
Liked
1:55
Listen as Dr. Alison Moskowitz discusses the difference between the safety profile of the new and emerging anti-PD-1 antibodies and chemotherapy.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
ELOQUENT-2 updates represent the longest median FU of an immuno-oncology agent in MM
1:43
1:43
Afspil senere
Afspil senere
Lister
Like
Liked
1:43
Dr. Sagar Lonial provides a brief update on the ELOQUENT-2 phase 3 trial and how it continues to demonstrate a benefit in terms of progression-free survival.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Optimal Pre-medication Strategy for Daratumumab
2:09
2:09
Afspil senere
Afspil senere
Lister
Like
Liked
2:09
Listen for just under two minutes as Dr. Harvey discusses optimal pre-medications for daratumumab, including H1 antagonists.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Rash Management for Patients Taking IRd (Ixazomib-Lenalidomide-Dexamethasone)
1:28
1:28
Afspil senere
Afspil senere
Lister
Like
Liked
1:28
Listen as Dr. Harvey will discuss rash management for patients taking IRd.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What is the appropriate management for severe hypercalcemia?
2:31
2:31
Afspil senere
Afspil senere
Lister
Like
Liked
2:31
Listen as Dr. Niesvizky explains the appropriate management for severe hypercalcemia.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What is the most common cause of renal failure in newly diagnosed patients with multiple myeloma?
1:54
1:54
Afspil senere
Afspil senere
Lister
Like
Liked
1:54
Listen as Dr. Niesvizky discusses the most common cause of renal failure in newly diagnosed patients with MM.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Standard dosing and delivery of Nal-IRI + 5-FU/LV
2:21
2:21
Afspil senere
Afspil senere
Lister
Like
Liked
2:21
Listen as Dr. Wang-Gillam discusses the standard dosing and delivery of Nal-IRI + 5-FU/LV.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How important is the availability of supportive care when considering transplant in older patients?
2:26
2:26
Afspil senere
Afspil senere
Lister
Like
Liked
2:26
Listen as Dr. Ritchie discusses the importance of available supportive care when considering transplant in older patients with MDS.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Is the AE profile of BV the same or different from traditional monoclonal antibody therapies?
2:09
2:09
Afspil senere
Afspil senere
Lister
Like
Liked
2:09
Listen as Dr. Moskowitz discusses the AE profile of BV and traditional monoclonal antibody therapies.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
When do you need to do a bone marrow biopsy in the management or assessment of multiple myeloma?
2:37
2:37
Afspil senere
Afspil senere
Lister
Like
Liked
2:37
Listen as Dr. Richter discusses when you need to do a bone marrow biopsy in the management or assessment of multiple myeloma.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What are some of the more common adverse reactions associated with brentuximab vedotin?
2:49
2:49
Afspil senere
Afspil senere
Lister
Like
Liked
2:49
Listen as Dr. Moskowitz discusses the more common adverse reactions associated with brentuximab vedotin and how they are most often managed.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What are the different technologies used to assess cytogenetic risk status?
2:17
2:17
Afspil senere
Afspil senere
Lister
Like
Liked
2:17
Listen as Dr. Richter will discuss the different technologies used to assess cytogenetic risk status in your myeloma patient.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What is meant by the term high-risk myeloma?
2:30
2:30
Afspil senere
Afspil senere
Lister
Like
Liked
2:30
Listen as Dr. Richter will discuss the meaning of high-risk myeloma.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Standard dosing and delivery of FOLFIRINOX
2:24
2:24
Afspil senere
Afspil senere
Lister
Like
Liked
2:24
Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of FOLFIRNOX in patients with pancreatic cancer.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The new FDA approval of pembrolizumab for cHL
4:36
4:36
Afspil senere
Afspil senere
Lister
Like
Liked
4:36
Listen as Dr. Anas Younes covers the new FDA approval of pembrolizumab for patients with cHL.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Standard dosing and delivery of gemcitabine/nab-paclitaxel
2:22
2:22
Afspil senere
Afspil senere
Lister
Like
Liked
2:22
Listen as Dr. Andrea Wang-Gillam explains standard dosing and delivery of gemcitabine/nab-paclitaxel in patients with pancreatic cancer.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How do I diagnose chronic myelomonocytic leukemia (CMML)?
3:35
3:35
Afspil senere
Afspil senere
Lister
Like
Liked
3:35
Listen as Dr. Rami Komrokji explains how to diagnose chronic myelomonocytic leukemia (CMML).Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What tests should I obtain upfront at the time of MDS diagnosis?
2:58
2:58
Afspil senere
Afspil senere
Lister
Like
Liked
2:58
Listen as Dr. Rami Komrokji discusses what tests to obtain upfront at the time of MDS diagnosis.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
How do I manage diarrhea in my patients taking ixazomib?
1:22
1:22
Afspil senere
Afspil senere
Lister
Like
Liked
1:22
Listen as Dr. Donald Harvey explains how to manage diarrhea in patients taking ixazomib.Af MediCom Oncology
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What prophylactic antithrombotic agents are safe to use with lenalidomide?
1:22
1:22
Afspil senere
Afspil senere
Lister
Like
Liked
1:22
Listen as Dr. Donald Harvey explains which prophylactic antithrombotic agents are safe to use with lenalidomide.Af MediCom Oncology
…
continue reading